MA32487B1 - Nouvelles pyridine-2-ones et pyridazine-3-ones substituees - Google Patents

Nouvelles pyridine-2-ones et pyridazine-3-ones substituees

Info

Publication number
MA32487B1
MA32487B1 MA33534A MA33534A MA32487B1 MA 32487 B1 MA32487 B1 MA 32487B1 MA 33534 A MA33534 A MA 33534A MA 33534 A MA33534 A MA 33534A MA 32487 B1 MA32487 B1 MA 32487B1
Authority
MA
Morocco
Prior art keywords
ones
compounds
btk
substituted pyridazine
new pyridine
Prior art date
Application number
MA33534A
Other languages
Arabic (ar)
English (en)
Inventor
Bradley E Loe
Yan Lou
Joel Mcintosh
Timothy D Owens
Michael Soth
Nolan James Dewdney
Rama K Kondru
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32487B1 publication Critical patent/MA32487B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Cette invention concerne des dérivés de 5-phényle-1h-pyridine-2-one et de 6-phényle-2h-pyridazine-3-one selon les formules générales i à iv, les variables r, x, y1, y2, y2', y3, y4, n et m étant définies comme décrit ici, qui inhibent btk. Les composés décrits ici sont utilisés pour moduler l'activité de btk et pour traiter les maladies associées avec une activité btk excessive. Les composés sont également utilisés pour traiter les maladies inflammatoires et auto-immunes associées avec la prolifération aberrante des lymphocytes b, comme la polyarthrite rhumatoïde. L'invention concerne également des compositions comprenant les composés de formules i à iv et au moins un vecteur, diluant ou excipient.
MA33534A 2008-06-24 2011-01-18 Nouvelles pyridine-2-ones et pyridazine-3-ones substituees MA32487B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7527708P 2008-06-24 2008-06-24
PCT/EP2009/057320 WO2009156284A1 (fr) 2008-06-24 2009-06-15 Nouvelles pyridine-2-ones et pyridazine-3-ones substituées

Publications (1)

Publication Number Publication Date
MA32487B1 true MA32487B1 (fr) 2011-07-03

Family

ID=40972952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33534A MA32487B1 (fr) 2008-06-24 2011-01-18 Nouvelles pyridine-2-ones et pyridazine-3-ones substituees

Country Status (25)

Country Link
US (4) US7902194B2 (fr)
EP (1) EP2297142B1 (fr)
JP (1) JP5536049B2 (fr)
KR (1) KR101299867B1 (fr)
CN (3) CN102066366B (fr)
AR (1) AR072272A1 (fr)
AU (1) AU2009264400B2 (fr)
BR (1) BRPI0914657A2 (fr)
CA (1) CA2728016C (fr)
CL (1) CL2010001483A1 (fr)
CO (1) CO6382183A2 (fr)
CR (1) CR11815A (fr)
EC (1) ECSP10010709A (fr)
ES (1) ES2552320T3 (fr)
IL (1) IL209141A0 (fr)
MA (1) MA32487B1 (fr)
MX (1) MX2010013191A (fr)
NZ (2) NZ588819A (fr)
PE (1) PE20100851A1 (fr)
PH (2) PH12012502374A1 (fr)
RU (1) RU2500680C2 (fr)
TW (1) TWI396537B (fr)
UA (1) UA103327C2 (fr)
WO (1) WO2009156284A1 (fr)
ZA (1) ZA201007816B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
CA2728683C (fr) * 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Nouvelles phenylpyrazinones en tant qu'inhibiteurs de kinases
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (fr) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibiteurs de la tyrosien kinase de bruton
KR101862327B1 (ko) * 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
WO2012030990A1 (fr) * 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridazinones, leur procédé de fabrication et leur procédé d'utilisation
HK1197060A1 (en) * 2011-08-17 2015-01-02 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US8669251B2 (en) * 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
EA027561B1 (ru) 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
JP5832664B2 (ja) 2011-12-09 2015-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
WO2013148603A1 (fr) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Dérivés de cinnoline en tant qu'en tant qu'inhibiteurs de la btk
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2881761A1 (fr) * 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibiteurs de la tyrosine kinase de bruton
US9458105B2 (en) * 2012-11-16 2016-10-04 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
JP6089124B2 (ja) 2013-03-05 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害薬
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
MX2015018038A (es) * 2013-07-03 2016-03-16 Hoffmann La Roche Compuestos de heteroaril-piridona y aza-piridona-amida.
CA2928568A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Procedes combinatoires permettant d'ameliorer l'avantage therapeutique du bisantrene
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
SG11201600378SA (en) 2013-07-30 2016-02-26 Gilead Connecticut Inc Formulation of syk inhibitors
US9260415B2 (en) 2013-12-05 2016-02-16 Genentech, Inc. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
KR101768402B1 (ko) * 2013-12-13 2017-08-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10570118B2 (en) * 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN109071496B (zh) 2016-03-31 2021-07-30 武田药品有限公司 异喹啉基三唑酮复合物
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
EP3728228A1 (fr) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020172431A1 (fr) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Formes solides de pyrazines condensées en tant qu'inhibiteur de syk
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1070056T3 (da) * 1998-03-14 2004-11-08 Altana Pharma Ag Phthalazinon-PDE III/IV-inhibitorer
MXPA01012442A (es) * 1999-06-03 2004-09-10 Abbott Gmbh & Co Kg Compuestos de benzotiazinona y benzoxazinona.
KR100681724B1 (ko) * 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
WO2004022562A1 (fr) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-arykl-imidazo[1,2-a]pyrazin-8-ylamines, procede de preparation et procede d'utilisation correspondants
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
WO2006099075A2 (fr) * 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
WO2006124731A2 (fr) 2005-05-12 2006-11-23 Irm Llc Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
DE602006020293D1 (de) 2005-08-29 2011-04-07 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin-kinasen nützlich sind
ATE528302T1 (de) 2005-08-29 2011-10-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
ATE548363T1 (de) * 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
CA2645583A1 (fr) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Procedes d'inhibition des proteines kinase btk et syk
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
HK1196358A1 (en) 2014-12-12
CN103408533B (zh) 2015-08-26
CN102066366A (zh) 2011-05-18
US7902194B2 (en) 2011-03-08
CA2728016A1 (fr) 2009-12-30
AR072272A1 (es) 2010-08-18
CR11815A (es) 2011-01-10
NZ588819A (en) 2012-08-31
MX2010013191A (es) 2010-12-17
TWI396537B (zh) 2013-05-21
EP2297142B1 (fr) 2015-10-14
CA2728016C (fr) 2017-02-28
PH12012502375A1 (en) 2013-06-17
HK1152940A1 (en) 2012-03-16
AU2009264400A1 (en) 2009-12-30
US20090318448A1 (en) 2009-12-24
NZ601700A (en) 2013-02-22
EP2297142A1 (fr) 2011-03-23
CL2010001483A1 (es) 2011-05-13
CO6382183A2 (es) 2012-02-15
CN103709148B (zh) 2015-10-21
WO2009156284A1 (fr) 2009-12-30
ZA201007816B (en) 2011-08-31
KR20110011706A (ko) 2011-02-08
CN103408533A (zh) 2013-11-27
JP5536049B2 (ja) 2014-07-02
AU2009264400B2 (en) 2014-05-01
RU2011101774A (ru) 2012-07-27
ES2552320T3 (es) 2015-11-27
US20140194413A1 (en) 2014-07-10
US20120129845A1 (en) 2012-05-24
US8124604B2 (en) 2012-02-28
UA103327C2 (en) 2013-10-10
IL209141A0 (en) 2011-01-31
US8618098B2 (en) 2013-12-31
RU2500680C2 (ru) 2013-12-10
BRPI0914657A2 (pt) 2019-09-24
CN102066366B (zh) 2014-04-16
US8822457B2 (en) 2014-09-02
PH12012502374A1 (en) 2014-11-12
PE20100851A1 (es) 2011-01-31
CN103709148A (zh) 2014-04-09
ECSP10010709A (es) 2011-01-31
US20110105479A1 (en) 2011-05-05
JP2011524404A (ja) 2011-09-01
KR101299867B1 (ko) 2013-08-23
TW201002683A (en) 2010-01-16

Similar Documents

Publication Publication Date Title
MA32064B1 (fr) Nouvelles pyridinones et pyridazinones
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA31763B1 (fr) Inhibiteurs de kinase de type polo
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
TNSN06369A1 (fr) Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3
MA32615B1 (fr) Inhibiteurs de cmet
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
PH12012502374A1 (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
TNSN08359A1 (fr) Derives d'amines
EP1796678A4 (fr) Carboxamide spirolactam cgrp receptor antagonists
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
WO2004091514A3 (fr) Antagonistes des recepteurs de cgrp
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA31683B1 (fr) Composes et procedes pour moduler fxr
IL157651A0 (en) N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
TNSN08196A1 (fr) Derives de pyrazine
EP1794133A4 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame